acute lung injury

Acute lung injury, and the more severe acute respiratory distress syndrome (ARDS), represent a spectrum of lung disease characterized by the sudden onset of pulmonary edema, inflammatory cell infiltration, and impaired oxygenation.1

The estimated incidence of ARDS in the United States is is between 150,000 and 200,000 cases per year in the United States, resulting in between 40,000 and 80,000 deaths per year.2,3

The Role of HGF and c-Met in Acute Lung Injury

The scientific literature indicates HGF and c-Met play important roles in mitigating the extent of lung injury, specifically in reversing alveolar damage and slowing lung fibrosis. In addition, studies indicate the importance of the HGF/c-Met pathway in attenuating lung injury during influenza infection.9,10,11

For instance, an animal model of influenza pneumonia investigating exogenous HGF and oseltamivir (an antiviral drug) demonstrated the administration of HGF in combination with oseltamivir improved outcomes over oseltamivir alone.12


  1. Walkey AJ, et al. 2012, Clinical Epidemiology
  2. Eworuke et al 2018, Journal of Critical Care
  3. Rubenfeld et all 2005, New England Journal of Medicine
  4. Shah et al 2017, Clin Chest Med
  5. WHO Interim Guidance COVID-19 Mar 2020
  6. Hirsch et al 2020, Kidney International
  7. Richardson et al 2020, Journal of the American Medical Association
  8. Medscape ARDS Mar 2020
  9. Panganiban & Day, 2011 Acta Pharmacologia Sinica
  10. Ito, et al 2014, Am J Physiology, Lung Cellular and Molecular Physiology
  11. Brauer, et al 2016 Am J Respiratory Critical Care Medicine
  12. Narasaraju et al 2014 CurrMolMed